

Centers for Medicare & Medicaid Services, HHS

§ 493.927

[57 FR 7151, Feb. 28, 1992, as amended at 58 FR 5229, Jan. 19, 1993; 68 FR 3702, Jan. 24, 2003]

EFFECTIVE DATE NOTE: At 87 FR 41236, July 11, 2022, §493.923 was amended by revising paragraphs (a) and (b)(1), effective July 11, 2024. For the convenience of the user, the revised text is set forth as follows:

§ 493.923 Syphilis serology.

(a) *Program content and frequency of challenge.* To be approved for proficiency testing for syphilis serology, a program must provide a minimum of five samples per testing event. There must be at least three testing events at approximately equal intervals per year. The samples may be provided through mailed shipments. An annual program must include samples that cover the full range of reactivity from highly reactive to non-reactive.

(b) * * *

(1) To determine the accuracy of a laboratory's response for qualitative and quantitative syphilis tests, the program must compare the laboratory's response with the response that reflects agreement of either 80 percent or more of 10 or more referee laboratories or 80 percent or more of all participating laboratories. Both methods must be attempted before the program can choose to not grade a PT sample.

* * * * *

§ 493.927 General immunology.

(a) *Program content and frequency of challenge.* To be approved for proficiency testing for immunology, the annual program must provide a minimum of five samples per testing event. There must be at least three testing events at approximately equal intervals per year. The annual program must provide samples that cover the full range of reactivity from highly reactive to nonreactive. The samples may be provided through mailed shipments or, at HHS' option, may be provided to HHS or its designee for on-site testing.

(b) *Challenges per testing event.* The minimum number of challenges per testing event the program must provide for each analyte or test procedure is five. Analytes or tests for which laboratory performance is to be evaluated include:

Analyte or Test Procedure

- Alpha-1 antitrypsin
- Alpha-fetoprotein (tumor marker)

- Antinuclear antibody
- Antistreptolysin O
- Anti-human immunodeficiency virus (HIV)
- Complement C3
- Complement C4
- Hepatitis markers (HBsAg, anti-HBc, HBeAg)
- IgA
- IgG
- IgE
- IgM
- Infectious mononucleosis
- Rheumatoid factor
- Rubella

(c) *Evaluation of a laboratory's analyte or test performance.* HHS approves only those programs that assess the accuracy of a laboratory's responses in accordance with paragraphs (c)(1) through (5) of this section.

(1) To determine the accuracy of a laboratory's response for quantitative and qualitative immunology tests or analytes, the program must compare the laboratory's response for each analyte with the response that reflects agreement of either 80 percent of ten or more referee laboratories or 80 percent or more of all participating laboratories. The proficiency testing program must indicate the minimum concentration that will be considered as indicating a positive response. The score for a sample in general immunology is either the score determined under paragraph (c)(2) or (3) of this section.

(2) For quantitative immunology analytes or tests, the program must determine the correct response for each analyte by the distance of the response from the target value. After the target value has been established for each response, the appropriateness of the response must be determined by using either fixed criteria or the number of standard deviations (SDs) the response differs from the target value.

Criteria for Acceptable Performance

The criteria for acceptable performance are—

Analyte or test	Criteria for acceptable performance
Alpha-1 antitrypsin	Target value ± 3 SD.
Alpha-fetoprotein (tumor marker)	Target value ± 3 SD.
Antinuclear antibody	Target value ± 2 dilutions or positive or negative.
Antistreptolysin O	Target value ± 2 dilution or positive or negative.

§ 493.927, Nt.

42 CFR Ch. IV (10–1–23 Edition)

Analyte or test	Criteria for acceptable performance
Anti-Human Immuno-deficiency virus.	Reactive or nonreactive.
Complement C3	Target value ±3 SD.
Complement C4	Target value ±3 SD.
Hepatitis (HBsAg, anti-HBc, HBeAg).	Reactive (positive) or non-reactive (negative).
IgA	Target value ±3 SD.
IgE	Target value ±3 SD.
IgG	Target value ±25%.
IgM	Target value ±3 SD.
Infectious mononucleosis	Target value ±2 dilutions or positive or negative.
Rheumatoid factor	Target value ±2 dilutions or positive or negative.

Analyte or test	Criteria for acceptable performance
Rubella	Target value ±2 dilutions or immune or nonimmune or positive or negative.

(3) The criterion for acceptable performance for qualitative general immunology tests is positive or negative.

(4) To determine the analyte testing event score, the number of acceptable analyte responses must be averaged using the following formula:

$$\frac{\text{Number of acceptable responses for the analyte}}{\text{Total number of challenges for the analyte}} \times 100 = \text{Analyte score for the testing event}$$

(5) To determine the overall testing event score, the number of correct re-

sponses for all analytes must be averaged using the following formula:

$$\frac{\text{Number of acceptable responses for all challenges}}{\text{Total number of all challenges}} \times 100 = \text{Testing event score}$$

[57 FR 7151, Feb. 28, 1992, as amended at 58 FR 5229, Jan. 19, 1993; 68 FR 3702, Jan. 24, 2003]

EFFECTIVE DATE NOTE: At 87 FR 41237, July 11, 2022, § 493.927 was amended by revising paragraphs (a), (b), and (c)(1) and (2), effective July 11, 2024. For the convenience of the user, the revised text is set forth as follows:

§ 493.927 General immunology.

(a) *Program content and frequency of challenge.* To be approved for proficiency testing for immunology, the annual program must provide a minimum of five samples per testing event. There must be at least three testing events at approximately equal intervals per year. The annual program must provide samples that cover the full range of reactivity from highly reactive to nonreactive. The samples may be provided through mailed shipments.

(b) *Challenges per testing event.* The minimum number of challenges per testing event the program must provide for each analyte or test procedure is five. Analytes or tests for which laboratory performance is to be evaluated include:

TABLE 1 TO PARAGRAPH (b)—ANALYTE OR TEST PROCEDURE

- Alpha-1 antitrypsin.
- Alpha-fetoprotein (tumor marker).
- Antinuclear antibody.
- Antistreptolysin O (ASO).
- Anti-human immunodeficiency virus (HIV).
- Complement C3.
- Complement C4.
- C-reactive protein (high sensitivity).
- HBsAg.
- Anti-HBc.
- HBeAg.
- Anti-HBs.
- Anti-HCV.
- IgA.
- IgG.
- IgE.
- IgM.
- Infectious mononucleosis.
- Rheumatoid factor.
- Rubella.

(c) * * *

(1) To determine the accuracy of a laboratory's response for quantitative and qualitative immunology tests or analytes, the

program must compare the laboratory's response for each analyte with the response that reflects agreement of either 80 percent or more of 10 or more referee laboratories or 80 percent or more of all participating laboratories. The proficiency testing program must indicate the minimum concentration that will be considered as indicating a positive response. Both methods must be attempted before the program can choose to not grade a PT sample.

(2) For quantitative immunology analytes or tests, the program must determine the correct response for each analyte by the distance of the response from the target value. After the target value has been established for each response, the appropriateness of the response must be determined by using either fixed criteria or the number of standard deviations (SDs) the response differs from the target value.

TABLE 2 TO PARAGRAPH (C)(2)—CRITERIA FOR ACCEPTABLE PERFORMANCE

The criteria for acceptable performance are— Analyte or test	Criteria for acceptable performance
Alpha-1 antitrypsin	Target value ± 20%.
Alpha-fetoprotein (tumor marker)	Target value ± 20%.
Antinuclear antibody (ANA) ...	Target value ±2 dilutions or positive or negative.
Antistreptolysin O	Target value ±2 dilutions or positive or negative.
Anti-Human Immunodeficiency virus (HIV)	Reactive (positive) or non-reactive (negative).
Complement C3	Target value ±15%.
Complement C4	Target value ±20% or ±5 mg/dL (greater).
C-reactive protein (HS)	Target value ±30% or ±1 mg/L (greater).
HBSAg	Reactive (positive) or non-reactive (negative).
Anti-HBc	Reactive (positive) or non-reactive (negative).
HBeAg	Reactive (positive) or non-reactive (negative).
Anti-HBs	Reactive (positive) or non-reactive (negative).
Anti-HCV	Reactive (positive) or non-reactive (negative).
IgA	Target value ±20%.
IgE	Target value ±20%.
IgG	Target value ±20%.
IgM	Target value ±20%.
Infectious mononucleosis	Target value ±2 dilutions or positive or negative.
Rheumatoid factor	Target value ±2 dilutions or positive or negative.
Rubella	Target value ±2 dilutions or positive or negative or immune or nonimmune.

* * * * *

§ 493.929 Chemistry.

The subspecialties under the specialty of chemistry for which a pro-

ficiency testing program may offer proficiency testing are routine chemistry, endocrinology, and toxicology. Specific criteria for these subspecialties are listed in §§ 493.931 through 493.939.

§ 493.931 Routine chemistry.

(a) *Program content and frequency of challenge.* To be approved for proficiency testing for routine chemistry, a program must provide a minimum of five samples per testing event. There must be at least three testing events at approximately equal intervals per year. The annual program must provide samples that cover the clinically relevant range of values that would be expected in patient specimens. The specimens may be provided through mailed shipments or, at HHS' option, may be provided to HHS or its designee for on-site testing.

(b) *Challenges per testing event.* The minimum number of challenges per testing event a program must provide for each analyte or test procedure listed below is five serum, plasma or blood samples.

Analyte or Test Procedure

- Alanine aminotransferase (ALT/SGPT)
- Albumin
- Alkaline phosphatase
- Amylase
- Aspartate aminotransferase (AST/SGOT)
- Bilirubin, total
- Blood gas (pH, pO₂, and pCO₂)
- Calcium, total
- Chloride
- Cholesterol, total
- Cholesterol, high density lipoprotein
- Creatine kinase
- Creatine kinase, isoenzymes
- Creatinine
- Glucose (Excluding measurements on devices cleared by FDA for home use)
- Iron, total
- Lactate dehydrogenase (LDH)
- LDH isoenzymes
- Magnesium
- Potassium
- Sodium
- Total Protein
- Triglycerides
- Urea Nitrogen
- Uric Acid

(c) *Evaluation of a laboratory's analyte or test performance.* HHS approves only those programs that assess the accuracy of a laboratory's responses in accordance with paragraphs (c)(1) through (5) of this section.